Physician profile
Rolf Freter
NPI 1457338576
$924.68
in general payments reported to CMS, 2019-2025
19 companies · $613 in 2025
The $613 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.11 · 2022: $58.51 · 2023: $154 · 2024: $61.23 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $139.38 | 2023-2025 | Reblozyl, Opdualag |
| Genentech USA, INC. | $102.30 | 2024-2025 | Polivy, Phesgo |
| Novartis Pharmaceuticals Corporation | $81.12 | 2023-2025 | |
| Glaxosmithkline, LLC. | $76.42 | 2024-2025 | Jemperli, Zejula |
| Pharmacyclics LLC, An Abbvie Company | $64.92 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $61.67 | 2025 | Enhertu, Lynparza, Tagrisso |
| Merck Sharp & Dohme LLC | $58.86 | 2025 | Keytruda |
| Myriad Genetic Laboratories, INC. | $48.99 | 2025 | Myrisk |
| Array Biopharma INC | $46.51 | 2025 | Braftovi, Lorbrena, Mektovi |
| Pfizer INC. | $41.82 | 2025 | |
| Genzyme Corporation | $31.28 | 2025 | |
| Janssen Biotech, INC. | $28.34 | 2022-2025 | Rybrevant |
| Mirati Therapeutics, INC. | $23.79 | 2023 | Krazati |
| Legend Biotech USA INC. | $23.20 | 2025 | Carvykti |
| Seagen INC. | $22.29 | 2023 | Padcev |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.35 | 2025 | |
| Agios Pharmaceuticals, INC. | $20.11 | 2025 | Pyrukynd |
| Astellas Pharma US INC | $18.18 | 2022 | |
| Lilly USA, LLC | $15.15 | 2025 | Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolf Freter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.